As potent weight loss agents, such as GLP-1 RAs, become more widely used in this population, it remains unclear how intentional weight reduction might influence outcomes in patients with heart failure particularly those with HFrEF, where the obesity paradox appears most pronounced. This evidence concerns the gene GLP1R and obesity disorder.